ArticleAnnals of nuclear medicine2026
Pseudotime-Based derivation of a PET-Based metabolic progression index for prognostic stratification in Extensive-Stage SCLC.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and validate a pseudotime-derived imaging biomarker integrating volumetric, metabolic, and spatial information from baseline 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18 F-FDG PET/CT) for prognostic stratification in patients with extensive-stage small cell lung cancer (SCLC).
methodsThis retrospective study included 83 patients with stage IV SCLC who underwent baseline 18 F-FDG PET/CT prior to systemic therapy. Whole-body tumor lesions were semi-automatically segmented, and conventional PET-derived metrics reflecting tumor burden, metabolic activity, inter-lesional heterogeneity, and spatial dissemination were extracted. A diffusion map–based manifold learning framework was applied to derive a latent progression axis, termed the Metabolic Progression Index (MPI), representing a pseudotime-based continuum of metastatic disease severity. The primary endpoint was 12-month all-cause mortality. Prognostic performance of MPI was evaluated using logistic regression, receiver operating characteristic (ROC) analysis, and internal bootstrap validation, and compared with conventional PET-derived parameters.
resultsDuring 12-month follow-up, 60 patients (72.3%) died. MPI showed strong correlations with spatial dissemination and moderate correlations with tumor burden metrics, without being fully explained by any single conventional parameter. In multivariable analysis, MPI emerged as an independent predictor of 12-month mortality (OR per 0.1-unit increase = 1.87, 95% CI: 1.41–2.62; p < 0.001). The MPI-based model demonstrated superior discriminative performance compared with conventional PET-derived models, with significant incremental prognostic value confirmed by likelihood ratio testing.
conclusionA pseudotime-based integration of baseline 18 F-FDG PET/CT features captures a latent continuum of metastatic disease architecture in extensive-stage SCLC. MPI provides prognostic information beyond conventional PET-derived metrics and may serve as a robust imaging biomarker for risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.